✦ LIBER ✦

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

✍ Scribed by Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Shuji Takei; Naomi Iwata; Hiroaki Umebayashi; Takuji Murata; Mari Miyoshi; Minako Tomiita; Norihiro Nishimoto; Tadamitsu Kishimoto

Book ID: 117302692
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 225 KB
Volume: 371
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(08)60454-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Abatacept in children with juvenile idio

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

✍ Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pér 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 213 KB

Safety and efficacy of oral ITF2357 in p

Safety and efficacy of oral ITF2357 in patients with active systemic onset juvenile idiopathic arthritis

✍ Jelena Vojinovic; Charles A. Dinarello; Antonio Furlan; Nemanja Damjanov; Carmin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Effect of interleukin-6 receptor inhibit

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

✍ Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Ro 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 197 KB

Efficacy and safety of sorafenib in pati

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

✍ Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 195 KB

Efficacy and safety of sorafenib in pati

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

✍ Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 195 KB

## Background: Most cases of hepatocellular carcinoma occur in the asia-pacific region, where chronic hepatitis b infection is an important aetiological factor. assessing the efficacy and safety of new therapeutic options in an asia-pacific population is thus important. we did a multinational phase

Efficacy and safety of golimumab in pati

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

✍ Robert D. Inman; John C. Davis Jr.; Désirée Van Der Heijde; Laura Diekman; Joach 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 2 views

## Abstract ## Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing spondylitis (AS) in the GO‐RAISE study. ## Methods Patients with active AS, a Bath AS Disease Activity Index (BASDAI) score ≥4, and a back pain score of ≥4 were randomly assigned in a 1.8:1.8:1